NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

Sponsor

Compugen Ltd

---

ClinicalTrials.gov Identifier: NCT04354246

Official Title: A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies

First Posted : April 21, 2020

Click here to see details on ClinicalTrials.gov

---

Drug: Dose escalation: COM902 monotherapy.

Combination Product: Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)

Drug: Cohort expansion: COM902 (RDFE) monotherapy.

Drug: Cohort expansion: COM902 in combination with COM701 (both at the RDFE).

---

COM 902

Anti-TIGIT Monoclonal Antibody COM902 (Code C174037)

Anti-TIGIT Monoclonal Antibody COM902

COM 902

COM-902

COM902

---

Locations

United States, Michigan

United States, Ohio

United States, Tennessee

United States, Texas